FDA Accelerated Approval Path

Nature Cell Advances JointStem U.S. Strategy with FDA Accelerated Approval Path and Nasdaq Roadmap

Dr. Ra Jeong-chan, Chairman of Naturecell, stated, “With the designation of JointStem as a Breakthrough Therapy, we have secured a foundation for close consultation with the FDA.” He added, “Based on advice from top FDA experts, we will validate our accelerated approval strategy at the meeting in May.” Dr. Ra…

Read More »